• Login
• Admin

Damerum, Luke (2024) Chemical and in silico exploration of novel 5-hydroxytryptamine 2A receptor (5-HT2AR) ligands. PhD thesis, University of Nottingham.

Preview

PDF (Thesis - as examined) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader Available under Licence Creative Commons Attribution. Download (5MB) | Preview

Abstract

The 5-HT2AR is a target in neuropsychiatric conditions such as psychosis, which is commonly managed with atypical antipsychotics. These have associated side effects due to off-target interactions. Consequently, there is a demand to develop therapeutics that exhibit no affinity for these off-target sites. Moreover, in recent 5-HT2AR X-ray crystal structures, a unique hydrophobic pocket or passage between transmembrane helices 4 and 5 sets it apart from other 5-HT2 receptor subtypes. This structural feature is implicated in the selectivity demonstrated by therapeutic pimavanserin towards the 5-HT2AR, owing to its binding conformation. Thus, presenting it as a target to interrogate for enhancing 5-HT2AR binding.

A structure-based approach was used to design a pimavanserin analogue series targeting transmembrane helices 4 and 5. In silico studies involving docking and MM-GBSA calculations using a 5-HT2AR homology model (RMSD 0.09 Å) predicted several analogues to demonstrate improved binding compared to pimavanserin. Synthesis of the series yielded low to moderate yields. To evaluate the binding of the series experimentally a cell membrane-based fluorescent time-resolved Förster resonance energy transfer (TR-FRET) methodology was chosen. This led to the development of a high-affinity 5-HT2AR fluorescent probe, and determination of kinetic rates, (Kd 1.74 ± 0.46 nM, Kon 1.96 ± 0.13 x 108 M−1 min−1, and Koff 0.42 ± 0.02 min−1) characterised at SNAP-tagged human 5-HT2AR expressed in Chinese hamster ovary membranes.

Item Type:	Thesis (University of Nottingham only) (PhD)
Supervisors:	Mistry, Shailesh Laughton, Charles Lane, Rob
Keywords:	5-HT2A, serotonin 2A receptor, GPCR, structure based drug design, membrane proteins
Subjects:	Q Science > QP Physiology > QP351 Neurophysiology and neuropsychology R Medicine > RM Therapeutics. Pharmacology
Faculties/Schools:	UK Campuses > Faculty of Science > School of Pharmacy
Item ID:	78719
Depositing User:	Damerum, Luke
Date Deposited:	13 Dec 2024 04:40
Last Modified:	13 Dec 2024 04:40
URI:	https://eprints.nottingham.ac.uk/id/eprint/78719

Actions (Archive Staff Only)

Edit View